HealthSport signs reseller agreement with TLMC
It is anticipated that the four products will launch in January 2009, and T Lynn Mitchell Companies (TLMC), with the execution of this agreement, placed an initial order
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).